Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a new standard in the treatment of advanced RET-mutant medullary thyroid cancer (MTC). The Phase 3 clinical trial distinctly highlights Retevmo’s superiority over existing first-line treatments, namely multikinase inhibitors cabozantinib and vandetanib. Retevmo demonstrated a statistically significant and […]
Eli Lilly and Company (NYSE: LLY) has unveiled top-line results from the LIBRETTO-431 study, which focused on the assessment of Retevmo against platinum-based chemotherapy plus pemetrexed in patients diagnosed with RET fusion-positive advanced non-small cell lung cancer (NSCLC). The findings showcased a notable improvement in progression-free survival (PFS), a primary objective of the study. Study […]
Eli Lilly’s oncology arm, Loxo@Lilly, disclosed that The New England Journal of Medicine (NEJM) has published an extensive analysis of results from the BRUIN Phase 1/2 trials on pirtobrutinib, a reversible Bruton’s tyrosine kinase (BTK) inhibitor. Pirtobrutinib is being investigated for use in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who […]
Loxo@Lilly, the oncology division of Eli Lilly and Company (Lilly), has secured the accelerated approval of the US Food and Drug Administration (FDA) for Jaypirca (pirtobrutinib) for the treatment of mantle cell lymphoma (MCL). To be available in 100mg and 50mg tablets, Jaypirca is specifically indicated for the treatment of adult patients having relapsed or […]
